---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157382"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:43:14.522869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up

## Summary
- FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.
- Cash and marketable securities $220.6M at April 30, 2025, providing runway into 2027.
- R&D expenses $71.7M (down from $86.2M); G&A expenses $116.3M (up from $54.3M) driven by pre-commercial costs.
- Entered licensing agreements for sebetralstat in Japan (Kaken, $11M upfront) and Canada (Pendopharm).
- Six global regulatory submissions under review; new clinical data presented at EAACI, C1-INH, and EAC.

## SEC filing metadata
- accession: 0001193125-25-157382
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/0001193125-25-157382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/d83017d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157382
- JSON: https://secwatch.observer/filing/0001193125-25-157382.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.